For laboratory use only. This product is intended for animal research only and not for use in humans.
Please enter valid quantity
Please log in to add favorites.
NULL OR EMPTY CART
Superhance™ 680 is a small molecule fluorescent in vivo blood pool imaging agent. Superhance 680 fluorescent imaging agent enables imaging of circulation, blood vessels, vasculature, vascular leak, including that associated with early oncologic and opthalmologic lesions. This agent binds to albumin in blood for extended (30m-1h) circulation.
|Fluorescent Agent Type||Vascular|
|Optical Imaging Classification||Fluorescence Imaging|
|Product Brand Name||Superhance|
|Quantity in a Package Amount||1.0 Units|
|Therapeutic Area||Vascular disease, Angiogenesis, Inflammation, Oncology/Cancer|
|Unit Size||1 Vial (10 doses)|
|Wave Length||680 nm|
Optical-based in vivo imaging of vascular changes and vascular leak is an emerging modality for studying altered physiology in a variety of different cancers and inflammatory states. A number of fluorescent imaging probes that circulate with the blood, but have no target selectivity, have been used to detect tumor leakiness as an indication of abnormal tumor vasculature. Inflammation is also characterized by distinct vascular changes, including vasodilation and increased vascular permeability, which are induced by the actions of various inflammatory mediators. This process is essential for facilitating access for appropriate cells, cytokines, and other factors to tissue sites in need of healing or protection from infection. This application note investigates the use of three fluorescent imaging probes, to detect and monitor vascular leak and inflammation in preclinical mouse breast cancer models.
Researchers trust our in vivo imaging solutions to give them reliable, calibrated data that reveals pathway characterization and therapeutic efficacies for a broad range of indications. Our reagents, instruments, and applications support have helped hundreds of research projects over the years. And our hard-earned expertise makes us a trusted provider of pre-clinical imaging solutions— with more than 9,000 peer reviewed articles as proof.
Superhance 680 is a small molecule fluorescent in vivo blood pool imaging agent. Superhance 680 enables imaging of circulation, blood vessels, vasculature, vascular leak, including that associated with early oncologic and opthalmologic lesions.
The primary goal of preclinical imaging is to improve the odds of clinical success and reduce drug discovery and development time and costs. Advances in non-invasive in vivo imaging techniques have raised the use of animal models in drug discovery and development to a new level by enabling quick and efficient drug screening and evaluation. Read this White Paper to learn how preclinical in vivo imaging helps to ensure that smart choices are made by providing Go/No-Go decisions and de-risking drug candidates early on, significantly reducing time to the clinic and lowering costs all while maximizing biological understanding.